2022 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
From my coverage universe, two Taiwanese stocks generated 59% and 71% returns in nearly six months. New product launch and geography expansion are...
686 Views
TWSE Short Interest Weekly (Dec 2nd): Walsin Lihwa, Gold Circuit, Lotus
We analyzed TWSE short interest report for the past week and highlight short interest changes in Walsin Lihwa, Gold Circuit, Lotus.
435 Views
Lotus Pharmaceutical (1795 TT): 3Q22 Review- Best-Ever Quarter, Aided by Oncology Drug Launch in US
In 3Q22, Lotus recorded 76% y/y and 85% q/q to NT$5.389 billion, driven by US launch of Lenalidomide capsules. Going ahead, growth will be mainly...
389 Views
Lotus Pharmaceutical (1795 TT): Ready for Next Phase of Growth with New Ownership and Product Launch
Lotus has already created a compelling position in ASEAN, which has been further augmented by oral oncology drug launch in Europe. New ownership...
228 Views
Lotus Pharmaceutical (1795 TT) Growth Story for Blood Cancer Drugs
Lotus’ profits will remain upbeat thanks to stable market share for its main product Suboxone and its anti-obesity drug business in South Korea....
228 Views